Kornimate/medical-research-clean huggingface dataset:
pilot intervention for social biases in eating disorders

Conditions: Eating Disorders; Anorexia Nervosa; Bulimia Nervosa; Binge-Eating Disorder

Summary: both behavioral, psychological, and cognitive differences related to social cognitive function have been related to illness-state in eating disorders, but interventions that directly target these problems are limited. this pilot intervention explores whether a brief art-therapy team-building intervention coupled with psychoeducation about social behavior can change self-concept or clinical symptoms in patients with eating disorders. participants will complete pre-treatment assessments related to social behaviors and clinical symptoms, attend four two-hour group sessions, and provide two follow-up post-treatment assessments at 1-4 weeks after the treatment and 3-5 months later. comparisons between the pre-intervention data and the first follow-up will be the primary outcome measures. the primary hypotheses are that participants will show increases in self-esteem and positive self-attributions and decreases in eating disorder symptoms after the intervention. the secondary hypothesis is that other clinical symptoms (depression, anxiety) will be improved after the intervention. feedback from participants about their experience with the study will assess perceived benefits as well as acquisition of the psychoeducation targets.

this project will recruit subjects with eating disorders in the dallas fort worth area. pre-assessment measures of anxiety, self-esteem, depression, eating disorder symptoms, and attributional style will be completed before the intervention. participants attend four weekly sessions of a group psychoeducational intervention. the intervention includes an art therapy experiential activity, psychoeducation on social function, reflection and discussion of sample videos and scripts, homework assignments, and guided discussions. post-assessments will be completed 1-4 weeks and 3-5 months after the interventions is completed. a. intake and screen: screening checklist for ed symptoms. demographic sheet; clinical history (low bmi); mini-international neuropsychiatric interview for dsm-v (mini); eating disorder assessment for dsm-v (eda-5); wechsler abbreviated scale of intelligence (wasi) b. pre/post measures (done at three time points, pre:1-4 weeks before intervention; post1: 1-4 weeks after intervention; and post2: 3-5 months after intervention). 1. internal, personal, and situational attribution questionnaire, (ipsaq) 2. state self-esteem scale (sse) 3. trait self-esteem scale (tse) 4. eating disorder examination questionnaire, (ede-q) 5. the quick inventory of depression, clinician-rated (qids) 6. structured interview guide for hamilton anxiety scale (sigh-a) c. feedback about the intervention is obtained from queries immediately after the last session and at the follow-up visits.

Eligibility criteria:
inclusion criteria: * eating disorder, current or recent * female * appropriate for partial hospital, intensive outpatient or outpatient treatment exclusion criteria: * medically unstable * in inpatient or residential treatment
nac effect on infertile women with endometrioma

Conditions: Female Infertility; Endometrioma; Stress Oxidative

Summary: oxidative stress has been investigated as a key factor in the pathogenesis and progression of endometrioma. high follicular fluid ros levels and serum can be related to negative ivf/icsi outcomes in infertile women with endometrioma. therefore, the use of antioxidants such as n-acetyl cysteine (nac) may be reduced complications of endometrioma. to study this hypothesis, we designed a double-blind, randomized clinical trial study that aimed to determine the effect of n-acetyl cysteine (nac) on stress oxidative factors and pregnancy outcomes in ivf/icsi cycles in endometrioma patients.

this study will be conducted at royan institute on 140 women with endometrioma who are eligible for the study after receiving written consent. after randomization, the participants will be divided into two intervention and control groups. then, they will be received 1200 (2×600) mg of effervescent tablets of nac or the placebo daily during 6 weeks simultaneous to start standard long agonist or antagonist protocols for induction. plasma blood will be collect before intervention and at the time of egg retrieval, in addition to, follicular fluid (ff) will be obtained from the mature follicles of each ovary and will be separated by centrifuging and will be frozen until analysis. then, we will measure the levels of two markers of oxidative stress (tac: total antioxidant capacity and sod: superoxide dismutase) in plasma and ff of all samples by enzyme-linked immunosorbent assay (elisa) method. in addition, the pregnancy outcomes will be investigated in treated and untreated groups. also, we will study the effect of pain severity of by visual analogue scale (vas) technique.

Eligibility criteria:
inclusion criteria: * age between 20 and 42 years * ultrasound or laparoscopic diagnosis of moderate to sever endometrioma (endometriosis stage iii and iv) * serum amh levels between 0.7 and 4.5 ng/ml * standard long gnrh and antagonist ovulation stimulation cycle * body mass index (bmi) \<30 kg/m2 exclusion criteria: * non-inclusion criteria: congenital uterine malformations * severe male infertility (tese, pesa) * past medical history of asthma

Keywords: en
esthetic and radiographic outcomes following immediate implant placement with thin or dehiscence buccal bone wall

Conditions: Jaw, Edentulous, Partially; Acquired Absence of Single Tooth

Summary: the aim of this prospective study was to evaluate the soft and hard tissue changes of immediate implant placement with buccal bone augmentation in sites with thin labial bone wall in the anterior maxillary zone.

the objective of this prospective controlled clinical trial is to compare the esthetic and radiographic outcomes following immediate implant placement with thin or dehiscences buccal plate using bone augmentation in combination with an absorbable collagen membrane. subjects in need of one implant replacing tooth to be removed in the maxilla within region 13-23 are included. at least 15 patients are recruited. no implant-supported temporary restorations are used during the first 4 months. after a screw-retained provisional phase of 2 months, a ﬁnal impression is taken at implant level and take-in definitive crown. patients are recalled for oral hygiene maintenance and prosthetic controls every 6 months for the entire duration of the study.

Eligibility criteria:
the inclusion criteria were as follows: 1. 18 to 70-year-old; 2. stable periodontal and systemic health (american society of anesthesiologists classification i or ii); 3. single maxillary anterior teeth (canine to canine); 4. bone thickness less than 1mm at 4mm apical to cementum-enamel junction (cej-4)； 5. presence of adjacent nature tooth; 6. good compliance; 7. no palatal vertical bone loss; 8. good oral hygiene. exclusion criteria are as follow: 1. uncontrolled periodontal or systemic disease; 2. general psychiatric contraindications; 3. more than 20 cigarettes per day; 4. history of head and neck radiotherapy； 5. pregnant or expecting to be pregnant; 6. patients with local or generalized healing limitations; 7. bruxism or other destructive parafunctional habits; 8. drug abuse or alcohol abuse.

Keywords: bone augmentation esthetics immediate implant buccal bone defects
mobile health for pacemaker patientes

Conditions: Cardiovascular Diseases; Sedentary Behavior; Anxiety Disorders; Depressive Disorder; Quality of Life

Summary: previous studies suggested that most patients with cardiac electronic implantable devices have a perception of describing the lifestyle due to a limitation of daily activities and physical exercise, besides the consequences in the psychological aspects such as anxiety and depression. the mhol-ceid is a randomized controlled trial that verifies the effectiveness of the mobile health of lifestyle that focuses on aspects of physical functional, psychosocial, and quality of life of patients with cardiac electronic implantable device.

cardiovascular diseases represent one of the main causes of death in the brazilian population, as well as dysfunctions of the heart conduction system. in an attempt to treat and correct heart conduction system dysfunctions, cardiac electronic implantable device (ceid) was developed. most people with ceid have a perception of describing the lifestyle due to a limitation of daily activities and physical exercise, besides the consequences in the psychological aspects such as anxiety and depression. these changes in the psychosocial conduct of patients with ceid are due to the lack of knowledge and the lack of effective guidance, being of fundamental importance to elaborate the resources of education in health for patients with ceid. health promotion through educational intervention is a recognized strategy and an internet approach to the mobile health proposal is a recognized and promising practice. this randomized controlled study is been conducted to verify the effectiveness of the mobile health of lifestyle that focuses on aspects of physical functional, psychosocial, and quality of life of patients with ceid. the hypothesis is that the use of mobile health of lifestyle provides greater physical functional, psychological aspects, and quality of life to patients with cied.

Eligibility criteria:
inclusion criteria: * written informed consent prior to randomization and any study procedure; * patients with any cied * access to the internet * clinical stability in the last 3 weeks * with left ventricular ejection fraction (lvef) greater than 40% * skill to conduct the self-monitoring of intensity in physical activity * new york heart association classification 1 or 2 exclusion criteria: * unstable angina * uncontrolled systemic arterial hypertension * cardiac arrhythmia effort- induced * people with a musculoskeletal or neurological problem * cognitive disability * patients opposed to the participation in the research * other concomitants cardiovascular disease, including uncontrolled diabetes mellitus (systemic hypertension without target-organ impairment is allowed); * moderate or severe chronic obstructive pulmonary disease;

Keywords: cardiovascular disease mobile health
metaneb® chest x-ray study

Conditions: Atelectasis

Summary: to study objective is to evaluate the impact of use of the metaneb® system in clearance of atelectasis, as demonstrated by improvement in chest x-rays. this is a a non-randomized open label study, with all subjects receiving treatment with the metaneb® system. subjects who qualify for enrollment in the study will receive therapy with the metaneb® system following the labeled instructions for the device. details of the treatment including duration and frequency will be defined in treatment procedures.

study population: post-surgical (thoracic, cardiac or abdominal surgery) non-mechanically ventilated patients with significant atelectasis as documented by chest x-ray results. duration of treatment: duration of treatment with the metaneb® system will be a minimum of 48 hours, or until the subject is discharged from the hospital (if discharge is earlier). enrolled subjects will remain in the study through day 4 or until the subject is discharged from the hospital, whichever occurs sooner.

Eligibility criteria:
inclusion criteria: * post-surgical (thoracic, cardiac or abdominal surgery) * age ≥ 18 years * significant atelectasis by chest x-ray * patient meets indication for therapy intervention as defined by recruitment and airway clearance protocol (respiratory department policy and procedure) * signed informed consent exclusion criteria: * cause of atelectasis suspected to be infectious or solid mass * requirement for mechanical ventilation * requirement for chronic supplemental oxygen * hemodynamically unstable, as defined by need for vasopressor therapy * anticipated need for mechanical ventilation or other poor clinical outcome, unrelated to atelectasis or secretion retention * contraindication to metaneb® therapy (untreated tension pneumothorax) * inability to perform metaneb® therapy using a mouthpiece * anticipated hospital discharge within 24 hours
caffeine in amblyopia study

Conditions: Amblyopia

Summary: prospective data on the visual acuity response in children treated by patching concurrently treated with caffeine and estimate the magnitude of effect that might be seen in a randomized trial (if no improvement in acuity is seen, this would be sufficient evidence to decide not to conduct a randomized, double blind trial). collect prospective data on the tolerability of caffeine in two dosages as an adjuvant treatment for amblyopia and provide limited data on its safety. evaluate the potential for a dietary intervention to enhance the acceptance and tolerability of patching on the child and family. demonstrate recruitment potential of subjects to participate in a dietary intervention study.


Eligibility criteria:
inclusion criteria: * amblyopia from strabismus and amblyopia exclusion criteria: * known intolerance to caffeine * diagnosis and/or treatment of attention deficit/hyperactivity disorder * presence of an ocular cause for reduced visual acuity * myopia with a special equivalent -6.00 diopters * current vision therapy or orthoptics - any type * ocular cause for reduced visual acuity * prior intraocular or refractive surgery * history of narrow-angle glaucoma * strabismus surgery planned within 16 weeks * nystagmus per se does not exclude the subject if the above visual acuity criteria are met * known skin reactions to patch or bandage adhesives * known allergy or intolerance to food dyes * current treatment with topical atropine eyedrops * menarche, pregnancy or lactation * use of any of the following medications which may affect caffeine metabolism: nafcillin, verapamil, fluvoxamine, ciprofloxacin and other fluoroquinolones, modafinil, nafcillin, and omeprazole

Keywords: caffeine
acute colon resection versus bridge to colon surgery with stent or stoma

Conditions: Colon Cancer

Summary: p) patients with acute obstructive colon cancer i) resection or bridge to surgery with stent or stoma c) emergency procedure o ) morbidity and mortality within 30 days, 90 day mortality and 3 \& 5 years overall survival

the aim of this prospective observational study is to evaluate primary resection for malignant obstruction of the colon compared to only decompression as first intervention regarding postoperative outcomes. we hypothesize that patients with malignant obstruction benefit from avoidance of emergency cancer resection, by a two-stage procedure, with decompression by a stoma or stent as first intervention, leading to decreased short-term morbidity and mortality and improved long-term oncological outcome.

Eligibility criteria:
inclusion criteria: * age \>18 years * symptomatic large bowel obstruction requiring acute intervention * ct-verified colon obstruction due to colon cancer independent of presence of metastases * informed consent exclusion criteria: * colonic perforation or bleeding * colonic obstruction of other origin than colon cancer * palliative situation
safety and efficacy of sofosbuvir + ribavirin in adolescents and children with genotype 2 or 3 chronic hcv infection

Conditions: Hepatitis C Virus Infection

Summary: this study will have two parts as follows: the pk lead-in phase of the study will evaluate the steady state pharmacokinetics (pk) and confirm the dose of sofosbuvir (sof) in hepatitis c virus (hcv)-infected pediatric participants. the pk lead-in phase will also evaluate the safety and tolerability of 7 days of dosing of sof+ribavirin (rbv) in hcv-infected pediatric participants. the treatment phase will be initiated by age cohort after confirmation of age-appropriate sof dosage levels. participants from the pk lead-in phase will immediately rollover into the treatment phase with no interruption of study drug administration. the treatment phase will evaluate the antiviral efficacy, safety, and tolerability of sof+rbv for 12 or 24 weeks in pediatric participants with genotype 2 or 3 hcv infection, respectively.


Eligibility criteria:
key inclusion criteria: * consent of parent or legal guardian required * chronic hcv infection genotype 2 or 3 * screening laboratory values within defined thresholds * pk lead-in only: all individuals must be treatment naive key exclusion criteria: * history of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol * co-infection with hiv, acute hepatitis a virus, or hepatitis b virus * clinical hepatic decompensation (ie, ascites, encephalopathy or variceal hemorrhage) * pregnant or nursing females * known hypersensitivity to study medication * use of any prohibited concomitant medications as within 28 days of the day 1 visit note: other protocol defined inclusion/exclusion criteria may apply.
genomic and dietary aspects in gastric cancer risk

Conditions: Gastric Cancer

Summary: gastric cancer (gc) ranks fourth in the number of deaths worldwide and it is sixth in italy with almost 9,000 deaths in 2020. survival of gc is one of the lowest reported amongst major cancers, thus making prevention a central priority for its control. however there is currently a lack of evidence on gastric cancer determinants. our study will pursue the following specific objectives: * analyze dietary and lifestyle habits for gc, also infrequent ones (wp1); * analyze major risk factors in rare patient subgroups (wp2); * develop a genome-wide modelling of polygenic risk score (prs) in gc (wp3)

the stomach cancer pooling project (stop) consortium dataset has grown to the current number of 35 studies from europe, america, middle east and eastern asia. it will be used as the cornerstone upon which the investigation on the dietary and lifestyle determinants of gastric cancer (gc) will be built. it will allow the analyses of relatively infrequent habits or exposures, genetic factors as well as to perform sufficiently powered analyses of interactions and subgroups that may present relevant heterogeneity in the etiological correlates of gc. the potential of genomics to personalize and thereby improve diagnosis, treatment, and prognosis of individuals has long been recognized, but so far evidence of the opportunity for genomics to drive prevention remains limited. recent advances in research on polygenic risk score (prs) have created new interest about the use of genetic information in prevention of common diseases and its application to risk stratification. a long-lasting open question is whether common genetic variants used to build prs are able to predict the risk of developing complex diseases with enough power to be used in a clinical setting. the lack of large enough dataset able to allow an unbiased prs validation, hampered this question to be answered for many years. this study builds upon the stop project (a consortium collecting data from about 13,500 gc cases and 32,000 controls) and the uk biobank (480 gc cases and 338,000 controls) to develop a polygenic risk score for gastric cancer.

Eligibility criteria:
inclusion criteria: * patients participating in studies that collaborate with the stop project * patient enrolled by the uk biobank exclusion criteria: * age \<18 years old * studies with less than 80 cases of histologically confirmed gastric cancer

Keywords: gastric cancer stop consortium genomics dietary aspects polygenic risk score gastric cardia carcinoma gastric neoplasm
balloon angioplasty for minor unstable stroke with intracranial atherosclerosis stenosis (bamus-icas)

Conditions: Ischemic Stroke

Summary: intracranial atherosclerotic stenosis (icas) is a common cause of stroke, especially in east and south asia, and is significantly associated with stroke recurrence and early neurological deterioration (end) despite aggressive medical management. minor stroke (national institutes of health stroke, nihss score ≤ 5) patients with icas often has higher risk of end. the early realization of blood flow patency is closely related to the improvement of patient outcomes. submaximal balloon angioplasty (sba) as a safer and simpler intervention which can improve cerebral blood flow. thus, sba may be an effective strategy for preventing end in acute ischemic stroke patients with icas.


Eligibility criteria:
inclusion criteria: 1. over 18 years of age; 2. minor ischemic stroke within 1 week of onset (nihss≤5); 3. have received the best drug treatment (dual antibody, anti-plate combined with anticoagulation), but symptoms still have measurable fluctuations or progression (nihss increased by at least 1 point); 4. symptoms fluctuate to the time of receiving balloon dilation within 24 hours; 5. the etiology was considered to be severe stenosis of the responsible vessels due to intracranial arteriosclerosis (70-99% stenosis), or perforator artery disease with severe stenosis of the carrier artery (confirmed by mra, cta or dsa); 6. patients with first onset or past onset without sequelae such as limb paralysis should not affect the score of this nihss, and mrs score of patients with past onset should be less than 2 points; 7. patients or family members sign informed consent. exclusion criteria: 1. patients who have developed large intracranial vessel occlusion; 2. intracranial hemorrhagic diseases in the past 3 months: cerebral hemorrhage, subarachnoid hemorrhage, etc.; 3. non-atherosclerotic disease-related stenosis: arterial dissection, moya-moya disease, arterioinflammatory disease, etc. 4. clotting disorders or systemic bleeding tendency or platelets less than 100,000; 5. complicated with serious infection or liver, kidney and other serious diseases; 6. patients with severe inability to control hypertension (systolic blood pressure \>200mmhg or diastolic blood pressure \>110mmhg); 7. women who are pregnant, have a pregnancy plan or are breastfeeding; 8. complicated with other serious diseases, life expectancy \< 6 months; other conditions deemed inappropriate for participation in this study.

Keywords: stroke submaximal balloon angioplasty early neurological deterioration intracranial atherosclerotic stenosis
development and evaluation of mhealth solutions to monitor and involve cardiometabolic patients in self-care

Conditions: Hypertension; Diabetes; Heart Failure; Copd; Asthma; Obesity

Summary: to develop, using barcode systems and virtual pillbox (tumedicina and alice), an app aimed at patients and carers of patients with cardiometabolic diseases as the main diagnosis, over 45 years of age, who have one or more pathologies and use one or more drugs on a daily basis and to analyze their effectiveness in terms of achieving therapeutic objectives, self-efficacy and self-efficacy in self-care or provision of care (as the case may be), healthy behavior, therapeutic compliance and safe use of medication.

in order to achieve the objective of this study, an experimental study will carry out on patients with cardiometabolic and respiratory diseases and their caregivers. a participation of 100 patients and 85 caregivers is planned. the aim is for them to use the mobile application developed over three months in order to evaluate their health improvement comparing several clinical and analytic parameters before and after the use of the app, and also evaluating the satisfaction of the participants.

Eligibility criteria:
inclusion criteria: * cardio-metabolic disease, respiratory disease or neurologic disease exclusion criteria: -